JP7520824B2 - 自動分析装置の前処理方法 - Google Patents
自動分析装置の前処理方法 Download PDFInfo
- Publication number
- JP7520824B2 JP7520824B2 JP2021518307A JP2021518307A JP7520824B2 JP 7520824 B2 JP7520824 B2 JP 7520824B2 JP 2021518307 A JP2021518307 A JP 2021518307A JP 2021518307 A JP2021518307 A JP 2021518307A JP 7520824 B2 JP7520824 B2 JP 7520824B2
- Authority
- JP
- Japan
- Prior art keywords
- magnetic beads
- sample
- measured
- substance
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002203 pretreatment Methods 0.000 title claims description 31
- 239000011324 bead Substances 0.000 claims description 191
- 239000000126 substance Substances 0.000 claims description 94
- 239000003153 chemical reaction reagent Substances 0.000 claims description 61
- 239000013076 target substance Substances 0.000 claims description 47
- 238000005259 measurement Methods 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 33
- 238000010828 elution Methods 0.000 claims description 31
- 125000000524 functional group Chemical group 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000012491 analyte Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000523 sample Substances 0.000 description 92
- 238000012545 processing Methods 0.000 description 85
- 230000007246 mechanism Effects 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 61
- 239000000243 solution Substances 0.000 description 49
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- 238000000034 method Methods 0.000 description 33
- 239000007788 liquid Substances 0.000 description 32
- 238000003756 stirring Methods 0.000 description 24
- 238000010586 diagram Methods 0.000 description 23
- 238000011534 incubation Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- 230000007723 transport mechanism Effects 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 239000002699 waste material Substances 0.000 description 12
- 108090000445 Parathyroid hormone Proteins 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 10
- 102100036893 Parathyroid hormone Human genes 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 5
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003398 denaturant Substances 0.000 description 4
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000007781 pre-processing Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- HXFCUMCLVYNZDM-UHFFFAOYSA-N 2-aminoacetic acid;sodium Chemical compound [Na].NCC(O)=O HXFCUMCLVYNZDM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- WCYJXDMUQGVQQS-UHFFFAOYSA-N pyridine;ruthenium Chemical compound [Ru].C1=CC=NC=C1 WCYJXDMUQGVQQS-UHFFFAOYSA-N 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- MUMGGOZAMZWBJJ-HZRGXLBSSA-N (8r,9s,10r,13s,14s,17s)-16,16,17-trideuterio-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC([2H])([2H])[C@@](O)([2H])[C@@]1(C)CC2 MUMGGOZAMZWBJJ-HZRGXLBSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LFGMBVOAGOMKBY-UHFFFAOYSA-N dimethyl(octadecyl)silicon Chemical compound CCCCCCCCCCCCCCCCCC[Si](C)C LFGMBVOAGOMKBY-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 octadecylsilyl Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
- G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
- G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00346—Heating or cooling arrangements
- G01N2035/00356—Holding samples at elevated temperature (incubation)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00465—Separating and mixing arrangements
- G01N2035/00534—Mixing by a special element, e.g. stirrer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/04—Details of the conveyor system
- G01N2035/0439—Rotary sample carriers, i.e. carousels
- G01N2035/0446—Combinations of the above
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Description
また、測定対象物質を含む試料に磁性ビーズを添加し、前記磁性ビーズに前記測定対象物質を結合させ、前記磁性ビーズを前記試料から摘出し、前記磁性ビーズから前記測定対象物質を溶出液によって分離する自動分析装置の前処理方法において、1アッセイプロトコール中で、前記試料に、複数種類の測定対象物質と結合する一種類の前記磁性ビーズを添加し、前記溶出液により、前記磁性ビーズから前記複数種類の測定対象物質を分離する前記前処理方法であって、前記磁性ビーズは、第1の種類の測定対象物質と結合する第1の抗体と、第2の種類の測定対象物質と結合する第2の抗体とが修飾され、前記試料に含まれる前記複数種類の測定対象物質の血中濃度比に応じて、前処理後の前記溶出液内に含有する前記複数種類の前記測定対象物質の混合比が均一化するように、前記第1の抗体と前記第2の抗体との量比を調整する。
図1は、本発明の実施例1による前処理方法を実行する自動分析装置の概略図である。
次に、本発明の実施例2について説明する。なお、実施例2による前処理方法も、図1に示した自動分析装置により実行される。
次に、本発明の実施例3について説明する。なお、実施例3による前処理方法も、図1に示した自動分析装置により実行される。
Claims (4)
- 測定対象物質を含む試料に磁性ビーズを添加し、前記磁性ビーズに前記測定対象物質を結合させ、前記磁性ビーズを前記試料から摘出し、前記磁性ビーズから前記測定対象物質を溶出液によって分離する自動分析装置の前処理方法において、
1アッセイプロトコール中で、
複数種類の測定対象物質と結合する一種類の前記磁性ビーズを、前記試料に添加し、
前記溶出液により、前記磁性ビーズから前記複数種類の測定対象物質を分離する前記前処理方法であって、
前記一種類の前記磁性ビーズは、測定試薬容器に収容され、
前記一種類の前記磁性ビーズは、
第1の種類の測定対象物質と結合する第1の抗体と、第2の種類の測定対象物質と結合する第2の抗体とを有し、
前記試料中に含まれる前記複数種類の測定対象物質の血中濃度比に応じて、前処理後の前記溶出液内に含有する前記複数種類の前記測定対象物質の混合比が均一化するように、前記測定試薬容器に収容された、前記磁性ビーズの前記第1の抗体の量比と前記第2の抗体の量比を調整する、
ことを特徴とする自動分析装置の前処理方法。 - 請求項1に記載の自動分析装置の前処理方法において、
前記磁性ビーズに応じた前記溶出液により、前記磁性ビーズから前記複数種類の測定対象物質を分離することを特徴とする自動分析装置の前処理方法。 - 請求項1に記載の自動分析装置の前処理方法において、
前記磁性ビーズは、官能基として前記第1の抗体および前記第2の抗体が表面に修飾された磁性ビーズであることを特徴とする自動分析装置の前処理方法。 - 測定対象物質を含む試料に磁性ビーズを添加し、前記磁性ビーズに前記測定対象物質を結合させ、前記磁性ビーズを前記試料から摘出し、前記磁性ビーズから前記測定対象物質を溶出液によって分離する自動分析装置の前処理方法において、
1アッセイプロトコール中で、
前記試料に、複数種類の測定対象物質と結合する一種類の前記磁性ビーズを添加し、
前記溶出液により、前記磁性ビーズから前記複数種類の測定対象物質を分離する前記前処理方法であって、
前記磁性ビーズは、第1の種類の測定対象物質と結合する第1の抗体と、第2の種類の測定対象物質と結合する第2の抗体とが修飾され、
前記試料に含まれる前記複数種類の測定対象物質の血中濃度比に応じて、前処理後の前記溶出液内に含有する前記複数種類の前記測定対象物質の混合比が均一化するように、前記第1の抗体と前記第2の抗体との量比を調整する、
ことを特徴とする自動分析装置の前処理方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019088019 | 2019-05-08 | ||
JP2019088019 | 2019-05-08 | ||
PCT/JP2020/009996 WO2020225971A1 (ja) | 2019-05-08 | 2020-03-09 | 自動分析装置の前処理方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JPWO2020225971A1 JPWO2020225971A1 (ja) | 2020-11-12 |
JPWO2020225971A5 JPWO2020225971A5 (ja) | 2022-04-12 |
JP7520824B2 true JP7520824B2 (ja) | 2024-07-23 |
Family
ID=73051365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518307A Active JP7520824B2 (ja) | 2019-05-08 | 2020-03-09 | 自動分析装置の前処理方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220276270A1 (ja) |
EP (1) | EP3968029A4 (ja) |
JP (1) | JP7520824B2 (ja) |
CN (1) | CN113785204A (ja) |
WO (1) | WO2020225971A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024101257A1 (ja) * | 2022-11-08 | 2024-05-16 | 株式会社日立ハイテク | 自動分析装置 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003527606A (ja) | 2000-03-16 | 2003-09-16 | バイアコア アーベー | 表面結合リガンドから溶出された分析物を捕捉するための方法 |
JP2004045395A (ja) | 2002-05-22 | 2004-02-12 | Sysmex Corp | 免疫測定方法、免疫測定装置、及び免疫測定用試薬 |
JP2004527732A (ja) | 2001-02-01 | 2004-09-09 | マグネティック バイオソリューションズ スウェーデン エービー | 方法 |
WO2005095969A1 (ja) | 2004-03-30 | 2005-10-13 | Universal Bio Research Co., Ltd. | 反応性色素結合磁性粒子及びタンパク質分離精製法 |
WO2006088192A1 (ja) | 2005-02-21 | 2006-08-24 | The University Of Tokyo | 分析用担体及びそれを用いる測定方法 |
JP2011504236A (ja) | 2007-11-20 | 2011-02-03 | スリーエム イノベイティブ プロパティズ カンパニー | ジアセチレンを含むポリマーセンサーを用いる細菌試料の分析方法 |
WO2014077400A1 (ja) | 2012-11-16 | 2014-05-22 | ユニバーサル・バイオ・リサーチ株式会社 | 直動型反応処理装置およびその方法 |
JP2016090570A (ja) | 2014-11-04 | 2016-05-23 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた対象物質の分離方法 |
CN106198963A (zh) | 2016-08-31 | 2016-12-07 | 上海美吉生物医药科技有限公司 | 一种用于捕获白细胞的免疫磁珠及其制备方法 |
JP2019049455A (ja) | 2017-09-08 | 2019-03-28 | 東芝テック株式会社 | 試料調製装置及び試料調製方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6027945A (en) * | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
AU2002255255A1 (en) * | 2001-05-07 | 2002-11-18 | Gamida Volcano Ltd. | Magnetic beads and uses thereof |
CN101273258A (zh) * | 2005-09-30 | 2008-09-24 | 卡钳生命科学股份有限公司 | 利用磁性珠纯化生物学组分的微流体装置 |
US20100137163A1 (en) | 2006-01-11 | 2010-06-03 | Link Darren R | Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors |
MY164038A (en) | 2010-10-29 | 2017-11-15 | Thermo Fisher Scientific Oy | System layout for an automated system for sample preparation and analysis |
WO2015025378A1 (ja) * | 2013-08-21 | 2015-02-26 | 株式会社日立製作所 | 試料分析方法及び試料分析装置 |
WO2016006398A1 (ja) * | 2014-07-07 | 2016-01-14 | 株式会社 日立ハイテクノロジーズ | 分析装置および分析方法 |
JP6256932B2 (ja) * | 2015-12-29 | 2018-01-10 | 株式会社アイスティサイエンス | 濃度の大きく異なる複数成分を含有する試料の分析前処理方法 |
CN108333357A (zh) * | 2018-02-09 | 2018-07-27 | 广州源起健康科技有限公司 | 一种磁珠时间分辨荧光免疫定量检测ck-mb试剂盒 |
-
2020
- 2020-03-09 EP EP20802846.4A patent/EP3968029A4/en active Pending
- 2020-03-09 CN CN202080032039.5A patent/CN113785204A/zh active Pending
- 2020-03-09 JP JP2021518307A patent/JP7520824B2/ja active Active
- 2020-03-09 WO PCT/JP2020/009996 patent/WO2020225971A1/ja active Search and Examination
- 2020-03-09 US US17/601,469 patent/US20220276270A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003527606A (ja) | 2000-03-16 | 2003-09-16 | バイアコア アーベー | 表面結合リガンドから溶出された分析物を捕捉するための方法 |
JP2004527732A (ja) | 2001-02-01 | 2004-09-09 | マグネティック バイオソリューションズ スウェーデン エービー | 方法 |
JP2004045395A (ja) | 2002-05-22 | 2004-02-12 | Sysmex Corp | 免疫測定方法、免疫測定装置、及び免疫測定用試薬 |
WO2005095969A1 (ja) | 2004-03-30 | 2005-10-13 | Universal Bio Research Co., Ltd. | 反応性色素結合磁性粒子及びタンパク質分離精製法 |
WO2006088192A1 (ja) | 2005-02-21 | 2006-08-24 | The University Of Tokyo | 分析用担体及びそれを用いる測定方法 |
JP2011504236A (ja) | 2007-11-20 | 2011-02-03 | スリーエム イノベイティブ プロパティズ カンパニー | ジアセチレンを含むポリマーセンサーを用いる細菌試料の分析方法 |
WO2014077400A1 (ja) | 2012-11-16 | 2014-05-22 | ユニバーサル・バイオ・リサーチ株式会社 | 直動型反応処理装置およびその方法 |
JP2016090570A (ja) | 2014-11-04 | 2016-05-23 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた対象物質の分離方法 |
CN106198963A (zh) | 2016-08-31 | 2016-12-07 | 上海美吉生物医药科技有限公司 | 一种用于捕获白细胞的免疫磁珠及其制备方法 |
JP2019049455A (ja) | 2017-09-08 | 2019-03-28 | 東芝テック株式会社 | 試料調製装置及び試料調製方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2020225971A1 (ja) | 2020-11-12 |
US20220276270A1 (en) | 2022-09-01 |
JPWO2020225971A1 (ja) | 2020-11-12 |
CN113785204A (zh) | 2021-12-10 |
EP3968029A1 (en) | 2022-03-16 |
EP3968029A4 (en) | 2023-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102658086B1 (ko) | 자동화된 임상 진단 시스템 및 방법 | |
Vogeser et al. | Progress in automation of LC-MS in laboratory medicine | |
US20210033503A1 (en) | Apparatus for automated analysis | |
US9128070B2 (en) | Analysis device | |
US8865418B2 (en) | Immunoanalytical method and system using mass spectrometry technology | |
US10876939B2 (en) | Apparatus for automated analysis | |
JPWO2010100816A1 (ja) | 分析装置 | |
JP2020521958A5 (ja) | ||
CN108780064B (zh) | 分析装置 | |
US20190293615A1 (en) | Method for tracking a sample idenitity during a process in an analysis system | |
WO2009014725A1 (en) | Versatile multichannel capillary biosensor system | |
US6149818A (en) | Method for separating components in liquid specimen and apparatus used in said method | |
JP7520824B2 (ja) | 自動分析装置の前処理方法 | |
JP7232841B2 (ja) | 自動分析装置 | |
JP7046070B2 (ja) | 分析系におけるプロセス中に試薬を同定するための方法 | |
JP7051871B2 (ja) | 分析系におけるプロセス中に試薬を同定するための方法 | |
KR20210117268A (ko) | Lc-ms 기초된 hba1c 계측을 위한 고속 표본 작업 흐름 | |
US20230333130A1 (en) | System and Method for Disposing of a Reaction Vessel of a Mass Spectrometry System | |
JP7026138B2 (ja) | 自動分析装置および分析方法 | |
WO2022069392A1 (en) | A method for determining the level of vitamin d and metabolites thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20210928 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240416 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240618 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7520824 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |